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Tropomyosin-related kinase (Trk) C, a member of the Trk family
of neurotrophin receptors, has been implicated in the growth and
survival of human cancer tissues. Here, we report that TrkC is
frequently overexpressed in human breast cancers and plays an
essential role in tumor growth and metastasis. Ectopic expression
of TrkC in non-malignant mammary epithelial cells suppressed
anoikis, which correlated with activation of the Ras-mitogen-
activated protein kinase and phosphatidylinositol-3-OH kinase
(PI3K)/Akt pathways, and reduced expression of the metastatic
regulator Twist. Furthermore, suppression of TrkC expression in
highly metastatic mammary carcinoma cells inhibited their
growth in vitro, as well as their ability to metastasize from the
mammary gland to the lung in vivo. These results have identified
TrkC as a critical regulator of breast cancer cell growth and
metastasis.
Introduction
The tropomyosin-related kinase (Trk) family of neurotrophin recep-
tors, TrkA, TrkB and TrkC, and their neurotrophin ligands primarily
regulate growth, differentiation and survival of neurons (1,2). Neuro-
trophins and their corresponding receptors have been shown to induce
a variety of pleiotropic responses in malignant cells, including en-
hanced tumor cell invasiveness and chemotaxis (3–7). TrkA and
TrkB have been shown to be integrally involved in neuroblastoma
biology (8,9), whereas TrkC is highly expressed in good-prognosis
neuroblastomas as well as medulloblastomas (10–12). In studies of
non-cutaneous cancers with a perineural invasive phenotype, such as
prostate carcinoma, it has been shown that the tumor cells acquire an
independent autocrine neurotrophin axis (13,14), and the observed
perineural invasion is associated with high nerve growth factor/Trk
presence (15). Roles for TrkA, TrkB and TrkC in carcinogenesis have
also been shown in basal cell carcinoma and cutaneous squamous cell
carcinoma (16). Malignant keratinocytes can express TrkA, B and C
as a unique survival pathway, and elevated levels of expression of
TrkA, B and C may predict perineural invasion in cutaneous squa-
mous cell carcinoma. A recent study shows that TrkB is a potent and
specific suppressor of caspase-mediated anoikis in non-malignant
epithelial cells (16). In this study, TrkB overexpression is shown
to be sufficient to transform non-malignant cells into invasive and
metastatic cells, by a mechanism that involves activation of the
phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway. This finding
suggests that TrkB might drive one or more facets of tumor forma-
tion and metastasis.
Although classical activation of TrkC occurs by receptor multime-
rization in response to ligand binding, TrkC activation in human
tumors seems to be largely attributable to overexpression of the
full-length protein. A variety of non-neuronal tissues have been shown
to express TrkC (4,10,16–19). A recent study shows that trkC gene in
breast, lung and pancreatic cancers compared with normal tissues
mutated within its kinase-encoding domain (20,21). The effect of
these mutations on kinase function remains to be determined, but their
positions within the protein suggest that many of them may affect
kinase function. The growing evidence suggests that TrkC overex-
pression could contribute to tumorigenesis, invasion and the meta-
static capability of cancer cells. Therefore, we examined the ability
of TrkC to drive malignant pathophysiology in a mouse mammary
tumor model and in human breast cancers.
Materials and methods
Cell culture and reagents
The breast cancer cell lines 67NR, 4T07, 4T1, ZR75B, SKBR3, MDA-MB-231
and Hs578T were purchased from American Type Culture Collection and
maintained in Dulbecco’s modified Eagle’s medium (DMEM) high glucose
(Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS), and the MCF7 cell line was maintained in RPMI1640
medium (Gibco) supplemented with 10% heat-inactivated FBS at 37C in
a humidified 5% CO2 incubator. Antibodies were obtained from the following
companies: anti-TrkC (C-14, 798), anti-HA(Y-11), anti-cyclin D1 (M-20) and
anti-Myc (9E10), from Santa Cruz Biotechnology (Santa Cruz, CA); anti-V5
from Invitrogen (Carlsbad, CA); anti-phospho-MAP kinase kinase (MEK)1/2,
anti-p44/42 mitogen-activated protein kinase (MAPK), anti-Poly (ADP-ribose)
polymerase (PARP), anti-caspase-3 and anti-phospho-Akt from Cell Signaling
Technology (Danvers, MA) and anti-b-actin from Sigma–Aldrich (St. Louis,
MO). The protein kinase inhibitors K252a, LY294002 and U0126 were
purchased from Calbiochem (Gibbstown, NJ).
Plasmids
Each of the two Synthetic RNA interference (siRNA)-encoding oligonucleo-
tides against mouse TrkC were designed and verified to be specific to TrkC by
BLAST search against the mouse and human genomes, respectively. To con-
struct hairpin-type single RNA interference vectors, 5 ll (100 mM) of the
synthesized sense and antisense oligonucleotides (supplementary Table 1 is
available at Carcinogenesis Online) were combined with 1 ll of 1 M NaCl and
annealed by incubation at 95C for 2 min, followed by rapid cooling to 72C
and ramp cooling to 4C over a period of 2 h. The mouse TrkC-siRNA insert
was subcloned into the XbaI/XhoI site of pFG12 lentiviral vector. A Control-
siRNA, which does not match any known mouse coding complementary DNA,
was used as a control.
Human tumor samples
Protein and RNA of human tissue samples were obtained from the Gangnam
Sevrance Hospital after approval by the institutional review board and ethics
committee of Gangnam Sevrance Hospital.
Immunoblotting and immunoprecipitation
Cells were lysed in a buffer containing 25 mM N-2-hydroxyethylpiperazine-
N#-2-ethanesulfonic acid (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10%
glycerol, 5 mM ethylenediaminetetraacetic acid and protease inhibitor mixture
(Complete; Roche, Gipf-Oberfrick, Switzerland). Extracts were separated by
sodium dodecyl sulfate/polyacrylamide gel electrophoresis followed by elec-
trotransfer to poly(vinylidene difluoride) membranes and probed with poly-
clonal or monoclonal antisera, followed by horseradish peroxidase-conjugated
secondary antibodies and visualized by chemiluminescence according to the
manufacturer’s instructions (Pierce, Rockford, IL). For immunoprecipitation,
the cell lysates were incubated with the appropriate antibody for 1 h, followed
Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal
bovine serum; MAPK, mitogen-activated protein kinase; MEK, MAP Kinase
kinase; MFP, mammary fat pad; mRNA, messenger RNA; PARP, Poly (ADP-
ribose) polymerase; PI3K, phosphatidylinositol-3-OH kinase; RT–PCR, reverse
transcription–polymerase chain reaction; siRNA, Synthetic RNA interference;
Trk, tropomyosin-related kinase.
 The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 1939
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on D
ecem
ber 22, 2013
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
by incubation with Gamma-bind beads GE Healthcare Co. (Piscataway, NJ) for
1 h at 4C. Beads were washed four times with the buffer used for cell solu-
bilization. Immune complexes then were eluted by boiling for 3 min in 2
Laemmli buffer (pH 6.8) and then extracts were analyzed by immunoblotting
as described above.
Soft agar assays
Soft agar assays were performed according to established protocols. 67NR and
4T1 cells infected with recombinant lentiviruses carrying either an empty
vector or an TrkC-siRNA were seeded in triplicate at a density of 8  103
cells per well in a six-well plate. Bottom layers were made up of 0.4% agar in
9% FBS and DMEM. Cells were resuspended in a top layer of 0.2% agar in 9%
FBS and DMEM. Cells were fed every other day by placing two drops of
medium on the top layer. After 3 weeks at 37C, colonies were stained with
p-iodonitrotetrazolium violet (2 lg/ml) for 16 h and macroscopic colonies
were counted (in quadruplicate).
Matrigel invasion assay
Breast cancer cell invasion was assayed in 24-well Biocoat Matrigel invasion
chambers (8 lm; BD Biosciences, Bedford, MA) according to the manufac-
turer’s protocol. Briefly, the top chamber was seeded with 2.5  105 viable
tumor cells in a serum-free medium with 0.5% bovine serum albumin. The
bottom chamber was filled with DMEM supplemented with 10% FBS as a che-
moattractant. After 16 h of incubation, the non-invasive cells that remained on
the upper surface of the membrane were removed with a cotton swab. Cells that
had invaded through the membrane were then fixed with methanol and stained
with hematoxylin (Vector, Burlingame, CA). Invasive cells per field were
counted for three random fields for each membrane, using a light microscope
at 200 magnification. Invasion assays were performed in triplicate.
Anchorage-independent cell growth
67NR and 4T1 cells infected with recombinant lentiviruses carrying either an
empty vector or an TrkC-siRNA were seeded into an Ultra Low Cluster plate
(Corning Life Sciences, Acton, MA) at 1 106 cells and photographed at 96 h.
Viral production and infection of target cells
293T cells were transfected with the transfer vector plasmid pFG12-siLuc
(empty) or pFG12-Mouse siTrkC (1604, 216) plasmid with the envelope-
encoding plasmid pHCMVG, the packaging plasmid pMDLg/pRRE and the
Rev-expression plasmid pRSV-Rev using the calcium phosphate method. The
supernatants were harvested 48 and 72 h after transfection, pooled, passed
through a 0.45 lm filter, ultracentrifuged for 2 h at 100 000g, resuspended
in 100 ll of 0.1% bovine serum albumin in phosphate-buffered saline, and the
lentiviral stocks were stored in small aliquots at 80C for titration and cell
infection. 67NR, 4T1 and Hs578T cells were plated in six-well plates (1  105
cells per well) and were cultured overnight. Lentiviruses were diluted in 2 ml
DMEM containing polybrene (8 lg/ml) and then centrifuged for 30 min at
1500 r.p.m. Twenty-four hours after infection, polybrene-DMEM was replaced
with fresh DMEM medium and the cells were cultured for other assays.
In vivo tumorigenicity and metastasis assay
All animals were maintained according to the National Cancer Institute’s
Animal Care and Use Committee guidelines, under approved animal study
protocols. For the spontaneous metastasis format, the left inguinal (#4) mam-
mary glands of anesthetized 7-week-old female BALB/cANCr mice (National
Cancer Institute-Frederick, Frederick, MD) were surgically exposed and 2 
105 4T1 cells (wild-type, Control-siRNA-expressing or si-TrkC-expressing)
were inoculated into the mammary fat pad (MFP) in a volume of 40 ll. The
mice (n 5 5–10 for each group) were euthanized 28 days after inoculation. At
the sacrifice time point, the MFP primary tumor and lungs were removed and
fixed in 10% buffered formalin. The MFP tumor volume was calculated by the
formula (S S L) 0.52, where S and L were the short and long dimensions,
respectively. Macroscopic quantitation of metastases was performed by count-
ing the number of nodules on the surface of the lung. For microscopic
quantitation of lung metastases, each lobe of the lung was processed for he-
matoxylin and eosin staining and evaluated by independently by two observers
(W.J. and C.Y.).
Reverse transcription–polymerase chain reaction
Total RNA was extracted using a Quizol reagent (Qiagen, Inc., Valencia, CA).
Reverse transcription was done using a one step Reverse transcription–
polymerase chain reaction (RT–PCR) kit according to the manufacturer’s
instructions (Qiagen, Inc.). Mouse TrkC RT–PCR forward primer is 3#-
CTTAACAAGTTCCTCAGGGCCCAT-5# and its RT–PCR reverse primer is
3#-AAGAATGTCCAGGTAGATCGGGGT-5#. Mouse Twist-1 RT–PCR for-
ward primer is 3#-CGGGTCATGGCTAACGTG-5# and its RT–PCR reverse
primer is 3#-CAGCTTGCCATCTTGGAGTC-5#. Human TrkC RT–PCR for-
ward primer is 3#-CTCTCCCAAATGCTCCACAT-5# and its RT–PCR reverse
primer is 3#-TCCGGTACA TGATGCTTTCA-5#. Mouse and human Gapdh
(Glyceraldehyde 3-phosphate dehydrogenase) RT–PCR forward primer is
3#-GACCCCTTCATTGACCTCAAC-5# and its RT–PCR reverse primer
is 3#-CTTCTCCATGGTGGTGAAGA-5#. Ploymerase chain reaction products
were separated on 1% agarose gels and visualized by ethidium bromide.
Immunohistochemistry
Routine formalin-fixed and paraffin-embedded excision biopsies of a series of
primary tumor and lung formed by 4T1 cells expressing either control-siRNA
or TrkC-siRNAs were analyzed. Immunohistochemistry was performed on
5 mm tissue sections. All specimens were immunostained with a non-biotin
detection system (Bond Polymer Refine; Leica Microsystems, Bannockburn,
IL), with diaminobenzidine development. Heat-induced antigen retrieval
was performed using Tris-ethylenediaminetetraacetic acid buffer (pH 9.0) in
a water bath at 95C for 30 min. Monoclonal anti-TrkC (clone 4G5, Abcam,
Cambridge, MA) were used. Stainings were performed with an automatic
immunostainer (Bond System; Leica Microsystems, Bannockburn, IL)).
Cell viability assay
The cell viability assay was performed using 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl tetrazolium bromide assay, which determines mitochondrial activity in
living cells. The cells were plated in 96-multiwell plates at a density of 1  104
cells per well and 100 ll of DMEM containing 3-(4,5-dimethylthiazole-2-yl)-
2,5-diphenyl tetrazolium bromide (0.5 mg/ml) was added to each well and
incubated in CO2 at 37C for 3 h. After the incubation period, the media were
removed and the cells were washed twice with phosphate-buffered saline. The
living cells can transform the tetrazolium ring into dark blue insoluble formazan
crystals solubilized with dimethyl sulfoxide, which can be quantified at 570 nm
using an enzyme-linked immunosorbent assay reader.
Analysis of apoptosis by annexin staining
4T1 cells expressing control-siRNA or TrkC-siRNAs and 4T1 cell treated with
K252a, LY294002 and U0126 were each seeded at a density of 1106 cells/ml
in 60 mm culture dishes and incubated for 24 h in a CO2 incubator. Apoptosis
was determined by an Annexin-V apoptosis detection kit (BD PharmingenTM,
San Jose, CA) according to the manufacturer’s protocol. Flow cytometric data
of 10 000 cells per sample were acquired on a FACS Calibur (Franklin Lakes,
NJ). Data were analyzed using the computer program Win MDI 2.8.
Results
Expression of TrkC in human breast tumor samples
TrkC is reported to be overexpressed in breast cancers compared with
normal tissues (22) and in brain metastases of breast carcinomas (23).
However, relatively little is known about whether TrkC activation is
essential for its contribution to the malignant properties of human
tumors. To further evaluate whether TrkC is an essential contributor
to carcinoma progression, we first determined whether expression of
TrkC correlated with certain pathological phenotypes in clinical
breast tumor samples. To do so, we measured TrkC messenger
RNA (mRNA) and protein expression in 38 normal and invasive
human breast tumors and compared these findings with histopatho-
logical criteria. About 84% of infiltrating ductal carcinoma (32 of 38
tumor samples) showed elevated TrkC expression compared with
normal their normal counterparts (Figure 1A and supplementary
Figure 1A and B is available at Carcinogenesis Online). We next
examined the elevated levels of TrkC associated with the increase
in phosphorylation of TrkC. Total tissue extracts were subjected to
immunoprecipitation with the anti-TrkC antibody followed by immu-
noblotting with the anti-phospho-tyrosine antibody. As shown in
Figure 1A, TrkC phosphorylation strongly increased in invasive
human breast tumors, suggesting that expression of TrkC may con-
tribute to the pathogenesis of human invasive breast carcinomas. We
next examined TrkC expression in a mouse mammary model system
that consists of three distinct tumor cell lines: 67NR, 4TO7 and 4T1.
All three cell lines are derived from a single mammary tumor that
arose spontaneously in a wild-type BALB/c mouse. 67NR cells form
primary tumors but cannot disseminate to distant tissues, including
blood, lymph nodes and lung. 4TO7 cells are able to spread from the
primary site to the lung but cannot establish visible metastatic
nodules. 4T1 cells are the most aggressive, able to complete all steps
of metastasis and efficiently form visible metastatic nodules in the
W.Jin et al.
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lung (24). Together, these tumor lines reflect the sequence of multistep
metastatic progression and therefore represent a valuable tool for
examining the role of Trk proteins in mammary tumorigenesis and
metastasis. We first compared the expression of neurotrophin recep-
tors in these cells and found that all three cell lines had low to un-
detectable trkA and trkB expression; RT–PCR analysis showed that
the 67NR cell line had negligible trkC expression, whereas trkC
mRNA was expressed in 4TO7 and 4T1 cell lines, with 5- to 10-fold
higher levels detected in 4T1 tumor cells compared with 4TO7 cells
(Figure 1B). Correspondingly, we also observed expression of TrkC
protein in 4TO7 and 4T1 tumor cells but not in 67NR cells and
analysis of tyrosine phosphorylation indicated that TrkC was tyrosine
phosphorylated in 4TO7 and 4T1 cells, indicating an activated state
(Figure 1B).
To determine whether TrkC is an important mediator of the tumor-
igenic capacities of the highly aggressive 4T1 cells, we examined
whether pharmacological inhibition of TrkC with CEP-701, an inhib-
itor of the Trk (NTRK) tyrosine kinases, would influence the ability of
Fig. 1. TrkC is overexpressed in mouse and human breast cancer cell lines and the inhibition of TrkC blocks colony formation and anchorage-independent growth
of 4T1 cells. (A) The expression profile of TrkC in human primary tumors. The RNA and protein of primary breast tumor tissue and normal tissue from breast
cancer patients were subjected to immunoprecipitation using anti-TrkC antibody, followed by immunoblotting with anti-TrkC antibody or anti-phospho-tyrosine
antibody. The endogenous b-actin levels were measured as internal controls. (B) Relative expression of TrkA, TrkB and TrkC in mouse breast cell lines (67NR,
4T07 and 4T1) was examined by RT–PCR. The endogenous Gapdh mRNA levels were measured as internal controls (upper panel). Assessment of TrkC
phosphorylation in mouse breast cancer cell lines (67NR, 4T07 and 4T1). Cell extracts were immunoprecipitated using anti-TrkC antobody and Gamma-bind
beads (Amersham Pharmacia Biosciences), followed by immunoblotting with anti-phospho-tyrosine antibody (lower panel). (C) Soft agar colony-forming assay
of mouse breast cancer cell lines. Monolayer cells were trypsinized, washed and plated in medium containing 0.2% agar to assess anchorage-independent growth.
Results are presented as the number of macroscopic colonies formed at 3 weeks after plating. (D) The 4T1 and 67NR mouse breast cancer cell lines seeded in
presence of serum into ultralow cluster plates and treated with CEP701 (200 nM) or vehicle control (dimethyl sulfoxide) for 7 days. Spheroid formation then
photographed at 200 magnification. (E) Expression of TrkC in human breast cell lines was examined by RT–PCR and immunoblotting. Endogenous Gapdh
mRNA levels and b-actin levels were measured as internal controls. (F) Hs578T cells treated after spheroid formation with K252a (200 nM), photographed at50
magnification 3 days later.
TrkC is a critical promoter of the tumor metastasis
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4T1 cells to survive and proliferate in an anchorage-independent
manner. Pretreatment with CEP-701 has been shown to completely
abolish neurotrophin-3 (NT-3)-induced tyrosine phosphorylation of
NTRK3 (25). After growing in soft agar for 15 days, 4T1 cells grown
in the presence of CEP-701 formed significantly fewer colonies than
untreated cells (Figure 1C). This result suggested that TrkC could be
affecting the survival of 4T1 cells. It is known that normal epithelial
cells to undergo programmed cell death in response to deprivation of
their extracellular matrix, by a process called anoikis. To mimic anoi-
kis in vitro, we used cell culture dishes to which 4T1 cells could not
attach. Under these conditions, 4T1 cells proliferated as large spher-
oid aggregates in suspension, whereas treatment of 4T1 cells with
CEP-701 markedly suppressed survival of 4T1 cells in suspension
(Figure 1D). This result suggested that TrkC promotes the survival
of 4T1 cells, perhaps by suppressing anoikis. To further investigate
the functional role of TrkC in apoptosis, we examined a cell viability
assay using 4T1 cells treated with K252a and 4T1 cells expressing
either control-siRNA or TrkC-siRNA. Growth of 4T1 cells treated
with K252a and 4T1 cells expressing TrkC-siRNA were significantly
inhibited compared with the control cells (supplementary Figure 2A
and E is available at Carcinogenesis Online). We examined whether
pharmacological inhibition of TrkC with K252a, an inhibitor of the
Trk (NTRK) tyrosine kinases, would influence the ability of 4T1 cells
to survive and proliferate. Indeed, 4T1 cells treated with K252a grew
more slowly than the parental cells (supplementary Figure 2D is
available at Carcinogenesis Online). Next, to identify the inhibition
mechanism of apoptosis by TrkC, we investigated the activation of
caspase-3 and the cleavage of PARP. As shown in supplementary
Figure 2B and F (available at Carcinogenesis Online), the 4T1 cells
expressing TrkC-siRNA and 4T1 cells treated with K252a signifi-
cantly increased the activation of caspase-3 and the cleavage of PARP
(an endogenous substrate of caspase-3) in comparison with the
control. To further characterize inhibition of apoptosis by TrkC, we
assessed the translocation of phosphatidylserine using annexin V. As
shown in supplementary Figure 2C and G (available at Carcinogen-
esis Online), cell numbers in lower right quadrants, which correspond
to early apoptosis cells (annexin V-positive), were increased up to 17-
fold in 4T1 cells expressing TrkC-siRNA and 4T1 treated with K252a
but 4T1 cells markedly decreased. To determine whether TrkC might
play a role in inducing the tumorigenic or metastatic properties of
human breast cancers, we examined whether TrkC expression was
detectable in several invasive human breast tumor cell lines, such as
MCF7, ZR-75, SKBR3, Hs578T and MDA-MB-231. We only ob-
served TrkC expression at the mRNA and protein level in the
Hs578T cell line, one of the invasive and metastatic human tumor
cell lines. In constrast, non-metastatic tumor cell lines, such as MCF7,
ZR-75 and SKBR3, did not express TrkC (Figure 1E). We also
examined whether TrkC functioned to suppress anoikis in these cells,
as was observed in the 4T1 model; indeed, whereas untreated Hs578T
cells proliferated as large spheroid aggregates in suspension,
treatment of Hs578T cells with K252a markedly suppressed survival
of Hs578T cells in suspension (Figure 1F).
TrkC is essential for tumor growth and can promote invasion
To further investigate the functional role of TrkC in breast cancer
progression, we used siRNA technology to knockdown TrkC expres-
sion in the highly metastatic 4T1 cells. This was achieved by design-
ing siRNA molecules that target sequences in the coding region of the
mouse trkC gene, infecting 4T1 cells with lentivirus encoding these
siRNAs and then selecting the cells stably expressing the siRNAs and
assessing knockdown efficiency. As shown in Figure 2A, expression
of two different siRNAs each markedly reduced the expression of trkC
mRNA and TrkC protein in 4T1 cells. A luciferase siRNA, whose
sequence did not match any known mouse gene, was used as a control.
As mentioned previously, the trkC gene is also known to be a part-
ner in the formation of the ETV6-NTRK3 (Tel-TrkC) fusion gene.
ETV6-NTRK3 appears to be linked to both the Ras-Erk1/2 and
the PI3K–Akt pathways (26,27). We next examined the activation
of the Ras-MAPK and PI3K–Akt pathways, as well as cyclin D1
expression, in pools of 4T1 cells in which TrkC expression was
silenced. Although levels of phosphorylated (activated) MEK1/2 and
PI3K–Akt, as well as cyclin D1 expression, were markedly higher in
4T1 cells compared with 67NR cells, knockdown of TrkC in the 4T1
cells significantly reduced levels of phosphorylated MEK1/2 and Akt
as well as cyclin D1 expression (Figure 2B). Akt is a serine/threonine
kinase belonging to the cyclic adenosine 3#,5#-monophosphate-
dependent protein kinase A/protein kinase G/protein kinase C super-
family of kinases. Its activation is induced in the course of signal
transduction by growth factors or insulin and it is involved in many
cellular processes, such as cell growth and survival, glucose metabo-
lism and transcriptional regulation (28). Akt is activated by phosphor-
ylation at both serine 308 and serine 473 by a kinase pathway initiated
by PI3K. The majority of the data indicate that Akt has critical roles in
cell growth, survival and apoptosis blockage by promoting the phos-
phorylation and subsequent cytoplasmic localization of many down-
stream proapoptotic protein targets (29). Consistent with this, Akt
signaling has been shown to be pretumorigenic. Immunohistochem-
istry studies have demonstrated that Akt is highly phosphorylated at
serine 473 in the majority of primary invasive breast tumors (30).
Since our data show that TrkC expression correlates with Akt activity,
we examined whether the phosphorylation status of Akt in primary
invasive breast tumor samples and adjacent normal tissue correlated
with TrkC expression in the same samples. Indeed, Akt was found to
be highly phosphorylated in primary invasive breast tumor samples,
which express TrkC protein (Figure 2C). To further investigate
whether the activation of Akt and MAPK by TrkC inhibits apoptosis,
we examined whether pharmacological inhibition of Akt or MEK1/2
with either LY294002, an inhibitor of PI3K or U0126, an inhibitor of
MEK1/2 would influence the ability of 4T1 cells to survive and pro-
liferate. Indeed, 4T1 cells treated with either LY294002 or U0126
grew more slowly than parental cells (supplementary Figure 3A is
available at Carcinogenesis Online). We examined cell viability assay
using 4T1 cells treated with either LY294002 or U0126. Growth of
4T1 cells treated with either LY294002 or U0126 significantly in-
hibited compared with the control cells (supplementary Figure 3B
is available at Carcinogenesis Online). Next, we investigated the
activation of caspase-3 and the cleavage of PARP. As shown in
supplementary Figure 3C (available at Carcinogenesis Online), the
4T1 cells treated with either LY294002 or U0126 significantly in-
creased the activation of caspase-3 and the cleavage of PARP (an
endogenous substrate of caspase-3) in compared with control. To
further characterize inhibition of apoptosis by Akt and MEK1/2
activation in 4T1, we assessed the translocation of phosphatidylser-
ine using annexin V. As shown in supplementary Figure 3D (avail-
able at Carcinogenesis Online), cell numbers in lower right
quadrants, which correspond to early apoptosis cells (annexin
V-positive), were significantly increased in 4T1 cells treated with
either LY294002 or U0126 but 4T1 cells markedly decreased. This
result suggested that activation of Akt and MEK1/2 by TrkC inhibits
apoptosis. We next examined whether knockdown of TrkC expres-
sion affects the ability of 4T1 cells to proliferate and invade in vitro.
Indeed, si-TrkC-expressing 4T1 cells grew more slowly than both
parental cells and 4T1 cells expressing control-siRNA (Figure 2D).
We also examined whether knockdown of TrkC affects anchorage-
independent growth of 4T1 cells. After growing in soft agar for
15 days, 4T1 cells expressing-trkC-siRNAs formed a significantly
lower number of colonies (Figure 2E).
Knockdown of TrkC significantly reduces colony formation in vitro
and tumor growth in vivo. To determine whether TrkC also plays an
important role in cancer invasion and metastasis, invasion through
Matrigel was assessed in 4T1 trkC-siRNA cells and the 4T1 control-
siRNA cells. In in vitro invasion assays, the pooled 4T1 trkC-siRNA
cells showed a 4- to 8-fold reduction in ability to invade through
Matrigel compared with parent and control cells (Figure 2F). In ad-
dition to being a direct effect on invasiveness, we should note that the
decreased invasion may also be due to a decreased proliferation rate as
this was shown to be an additional consequence of TrkC inhibition
(Figure 2E).
W.Jin et al.
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To explore whether increased expression of TrkC could stimulate
breast cancer progression-related biological responses, 67NR cells
were infected with recombinant retroviruses carrying a TrkC comple-
mentary DNA or empty MSCV vector as a control. Individual positive
transformants were obtained by puromycin selection. Expression of
the predicted 140 kD TrkC protein in transformed cells was verified
by immunoblotting using the anti-TrkC (C-14) antibody (Figure 3A).
We also examined whether the ectopically expressed TrkC was phos-
phorylated in these cells; all TrkC in 67NR cells expressing TrkC
appeared to be autophosphorylated, probably by endogenous NT-3
(Figure 3A). To test whether TrkC expression affects the Ras-Erk1/
2 and the PI3K–Akt pathways, we examined the activation states of
MEK1/2 and Akt as well as total cyclin D1 levels in 67NR cells
expressing TrkC. Levels of phosphorylated MEK1/2 and Akt, as well
as cyclin D1 expression, were enhanced markedly in TrkC-expressing
cells (Figure 3B). We also examined whether TrkC expression affects
the anchorage-independent growth of 67NR cells. After growing in
soft agar for 15 days, 67NR cells expressing trkC formed colonies;
this was not seen in control cells (Figure 3C). Together, these data
demonstrate that TrkC induces the activation of Ras-Erk1/2 and the
PI3K–Akt pathways, events that may support the growth and tumor-
igenicity of breast tumors.
Twist is a highly conserved basic helix-loop-helix transcription
factor, which is implicated as an oncogene. A recent study showed
that Twist, a master regulator of morphogenesis, plays an essential
role in metastasis and that Twist mRNA is expressed in 4T1 cells (31).
To elucidate association between TrkC and Twist, we examined
whether expression of TrkC was able to induces endogenous Twist
gene in 67NR cells; indeed, the expression of Twist gene was mark-
edly enhanced in 67NR cells overexpressing TrkC (Figure 3D).
Therefore, we also examined whether knockdown of TrkC affects
the expression of Twist in 4T1 cells. Indeed, knockdown of TrkC
reduced expression of Twist gene (Figure 3E). To see whether the
increasing levels of TrkC further activate Twist-1, we transfected
TrkC in T-47D tet-on cell lines using a tetracycline-inducible system
and examined the Twist activation. The expression of TrkC was con-
ditionally regulated by the application of doxycyline and we demon-
strated that the expression level of Twist genes was increased
Fig. 2. Suppression of TrkC expression by stable TrkC-siRNA reduces cell proliferation and colony formation. (A) The protein and RNA of TrkC expression were
examined by immunoblotting and RT–PCR in 4T1 cells stably expressing Control-siRNA, TrkC-siRNA #1 or TrkC-siRNA #2. The endogenous b-actin and Gapdh
mRNA levels were measured as internal controls. (B) Parental 4T1 and 4T1 cells expressing either control-siRNA or TrkC-siRNAs were serum starved overnight
in 0.5% serum and then stimulated with and without 10% FBS at the indicated times (0, 1, 4 and 6 h). Whole-cell lysates were prepared for western blotting and
probed with antibodies against the phosphorylated forms of Mek1/2 (ser217/221), phosphorylated Akt (Ser 473) and cyclin D1. (C) The expression profile of
phospho-Akt in human primary tumors. The protein of primary breast tumor tissue and normal tissue from breast cancer patients was subjected to immunoblotting
with antiphospho-Akt antibody. The endogenous b-actin levels were measured as internal controls. (D) Population doublings of wild-type 4T1 and 4T1 cells
expressing either control-siRNA or TrkC-siRNAs. Each data point represents the mean of cells counted in triplicate dishes. (E) Anchorage-independent growth of
67NR control cells or 67NR and 4T1 cells expressing either control-siRNA or TrkC-siRNAs. The number of soft agar colonies presented is the mean of colony
counts in 50 microscopic fields from three dishes. (F) Cell invasion assay. Parental 4T1 and 4T1 cells expressing either control-siRNA or TrkC-siRNAs were
induced to invade toward serum. After 16 h of incubation, cells that traversed the Matrigel-coated filters were stained and counted (P , 0.05).
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depended on TrkC expression (Figure 3F). These results suggest that
TrkC is a regulator of Twist expression and indicates that elevated
TrkC expression might therefore contribute to the malignant behavior
of breast tumors through the induction of these important oncogenic
mediators.
Knockdown of TrkC significantly reduces tumor growth and
metastasis in vivo
To determine whether TrkC plays a causal role in tumor growth and
metastasis, we tested whether suppression of TrkC expression in the
highly metastatic 4T1 cells would affect their growth potential and
metastatic ability in vivo. We injected pools of 4T1 cells carrying
either the trkC-siRNAs or the control-siRNA into the MPFs of
BALB/c mice and measured the growth of the resulting primary tumors
weekly. Parental and si-control 4T1 cells formed primary mammary
tumors at identical rates, whereas primary tumor formation by 4T1
cells carrying either of the two trkC-siRNAs was markedly decreased
(Figure 4A and B). Histological examination revealed that the primary
tumors formed by the trkC-siRNA cells and the control-siRNA cells
were both undifferentiated mammary carcinomas (Figure 4C). We
then performed immunohistochemistry with a TrkC-specific antibody
on tumor tissues. Interestingly, TrkC expression reduced in primary
tumors from mice injected with the trkC-siRNA-expressing cells
when compared with the control counterparts and an enhanced ex-
pression of TrkC is seen in cancer cells with spindle shaped Sarco-
matous morphology (Figure 4D). We believe that primary tumors
formed by the injection of the trkC-siRNA cells may have arisen from
4T1 cells in which TrkC expression was minimally suppressed since
we used pooled populations of trkC-siRNAs without clonal selection.
As shown Figure 2A, knockdown of trkC was not complete in the 4T1
trkC-siRNA stable cell lines. Our results suggest that TrkC is required
for primary tumor formation by 4T1 cells.
To determine whether loss of TrkC expression affects the ability of
4T1 cells to metastasize in vivo, we examined the metastatic capacity
of 4T1 cells expressing either the trkC-siRNAs or the control-siRNA.
Four weeks after mammary gland implantation of cells, mice were
killed and the lungs were examined for metastatic lesions by
inspection under a dissection microscope. Indeed, mice injected with
Fig. 3. TrkC induces elevated levels of phophorylated Akt, phosphorylated MEK1, Twist-1 and cyclin D1. (A) Analysis of TrkC protein expression using
anti-TrkC antibody (left panel). Assessment of TrkC phosphorylation in 67NR cell lines stably expressing control vector or TrkC. Cell extracts were
immunoprecipitated using anti-V5 antibody and Gamma-bind beads (Amersham Pharmacia Biosciences), followed by immunoblotting with anti-phospho-tyrosine
antibody (right panel). (B) Immunoblot analysis of the phosphorylated forms of Mek1/2 (ser217/221), phosphorylated Akt (Ser 473) and cyclin D1 in 67NR
cells expressing a control vector or TrkC. (C) Anchorage-independent growth of 67NR control cells or 67NR and 4T1 cells expressing either control-siRNA
or TrkC-siRNAs. The number of soft agar colonies presented is the mean of colony counts in 50 microscopic fields from three dishes. Representative photos
are presented as macroscopic colonies formed at 3 weeks after plating. (D) RT–PCR analysis of TrkC and Twist mRNA expression in 67NR cell lines stably
expressing control vector or TrkC. (E) Expression of TrkC and Twist mRNAs was examined by RT–PCR in 4T1 cells stably expressing Control-siRNA,
TrkC-siRNA #1 or TrkC-siRNA #2. The endogenous Gapdh mRNA levels were measured as internal controls. (F) Induction of TrkC expression by doxycycline
increased the level of Twist-1 in T-47D tet on cells. Cells were cultured for 0–48 h in the presence (2 lg/ml) and absence of doxycycline. The protein and
RNA of TrkC and Twist expression were examined by immunoblotting and RT–PCR.
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trkC-siRNA-transfected cells had significantly fewer metastatic lung
nodules than the control counterparts (Figure 5A). Histological
analyses confirmed that the number of micrometastatic lesions
was also drastically reduced in the lungs of mice carrying trkC-
siRNA-expressing tumors (Figure 5B and C). Also, phospho-Akt
expression was markedly reduced in the lungs of mice carrying
trkC-siRNA-expressing tumors (Figure 5D).
Taken together, these results clearly show that the knockdown of
TrkC reduced lung colonization in vivo following implantation of
breast cancer cells in the mammary glands. Thus, TrkC seems to be
critical in promoting the efficiency of one or more steps in the met-
astatic process.
Discussion
There is currently great interest in understanding how oncogenic ty-
rosine kinases function in malignant transformation as these proteins
are attractive targets for therapeutic intervention (32). The prevalence
of overexpression of the Trk family of neurotrophin receptors in hu-
man cancers has also prompted interest in these receptors as potential
therapeutic targets (33). In the present study, we showed that TrkC is
highly expressed in primary human breast tumors and provided evi-
dence that TrkC is a critical promoter of breast carcinogenesis by
demonstrating that TrkC knockdown significantly reduced tumor
growth and metastasis of a highly metastatic mammary tumor cell
line in vivo.
The Trk family of receptors is emerging as an important player in
carcinogenic progression. Trks appear to have a high capacity for
ligand-independent activation; this has been shown to occur via spon-
taneous interaction and subsequent autophosphorylation of receptors
when Trks are expressed at high levels (34). Many tumors express one
or more Trk receptors that may drive aspects of tumor formation and
metastasis. Rat intestinal epithelial cells expressing TrkB have been
shown to resist anoikis by triggering the activation of the PI3K–Akt
cascade (17). TrkA and TrkC can be activated in cancer by chromo-
somal localization and transcriptional orientation of Trks and its re-
arranging partners. Somatic rearrangements of TrkA (NTRK1), which
produces chimeric oncogenes with constitutive tyrosine kinase activ-
ity, have been detected in a consistent fraction of papillary thyroid
tumors (35). ETV6-NTRK3 (tel-trkC) fusion transcripts have been
identified in congenital fibrosarcoma (a pediatric spindle cell malig-
nancy of the soft tissues), cellular mesoblastic nephroma, acute my-
eloid leukemia and human secretory breast carcinoma, a rare subtype
of infiltrating ductal carcinoma (26,27,36). This fusion gene encodes
a unique fusion protein containing the helix-loop-helix protein dimer-
ization domain of Tel and the catalytic domain of TrkC and may
contribute to oncogenesis by dysregulation of signal transduction
pathways downstream of TrkC. Indeed, expression of ETV6-NTRK3
causes the transformation of NIH3T3 cells (37), a process that is
marked by the induction of cyclin D1 and is dependent on two major
effector pathways of wild-type TrkC, the Ras-MAPK pathway and the
PI3K–Akt pathway (37).
Fig. 4. Suppression of TrkC expression slows primary tumor growth of 4T1 cells in the mammary gland. (A, B) Tumor volumes in primary mammary
tumors formed by 4T1 cells expressing either control-siRNA or TrkC-siRNAs. Each data point represents the mean of each type of primary tumor. (C)
Hematoxylin and eosin staining of the primary mammary tumors formed by 4T1 cells expressing either control-siRNA or TrkC-siRNAs (magnification: 200).
(D) Immunohistochemical analysis of TrkC protein levels in primary mammary tumors from mice injected with parental 4T1, 4T1 cells expressing control-siRNA
or TrkC-siRNAs (magnification: 200).
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TrkC is frequently overexpressed in human cancers including pan-
creatic and prostate carcinoma, medulloblastoma, pediatric brain tu-
mor, neuroblastoma, leiomyosarcoma and basal cell and cutaneous
squamous cell carcinomas (11,15,17,38–41). Although it is known
that overexpression of TrkC confers constitutive activation of its ty-
rosine kinase activity to induce continuous proliferation of the cell, it
has been unclear whether deregulated TrkC can act in an oncogenic
fashion in human tumors. We have found that expression of TrkC
activates mitogenic and survival pathways in breast cancer cells,
and therefore confers potent tumorigenic, invasive and metastatic
capacities, suggesting that TrkC may indeed directly contribute to
human malignancies.
Metastasis is a complex multistep process, during which tumor
cells spread from the primary tumor mass to distant organs. Recent
evidence indicates Twist plays a key role in the metastasis of breast
cancer, by promoting epithelial-to-mesenchymal transition. Downre-
gulation of Twist was shown to suppress metastatic ability by block-
ing mesenchymal-to-epithelial transition in an in vivo system (31).
Twist is a highly conserved basic helix-loop-helix transcription factor,
which is implicated as an oncogene. Increased expression of Twist has
been found in various human cancers, including melanoma, T-cell
lymphoma, rhabdomyosarcoma and gastric carcinomas (42–45). Al-
though regulation mechanism of Twist by TrkC remain unknown, we
have shown here that TrkC is an upstream regulator of Twist expres-
sion; antagonism of TrkC may therefore represent an effective ap-
proach for the treatment of breast cancers that are dysregulated in
TrkC and/or Twist signaling pathways.
TrkC is known to promote survival and neurogenesis via two pri-
mary signaling pathways, the PI3K and MEK pathways, which are
common downstream substrates of many receptor tyrosine kinases
(46). Our data demonstrated that knockdown of TrkC almost com-
pletely inhibited the PI3K and MEK pathways, consequently reduc-
ing cell survival and anchorage-independent growth, whereas
ectopic TrkC expression in epithelial cells induced anchorage-
independent growth and activated the PI3K and MEK pathways.
Deregulation of the PI3K pathways has been reported in all major
types of epithelial cancer, and our data suggest that in breast cancer,
deregulation of PI3K pathway can be caused by the overexpression
of TrkC.
In summary, our findings suggest that inhibition of TrkC kinase
activity may have a notable impact on the tumorigenic and metastatic
capacities of human breast cancers with overexpressed TrkC. There-
fore, the role of TrkC in the development and progression of human
breast cancer deserves further attention.
Fig. 5. Suppression of TrkC expression inhibits metastasis of 4T1 cells to the lung. (A) Total numbers of lung metastatic nodules in each mouse of each group
were counted under the dissection scope. Two populations of 4T1 cells infected independently with TrkC-siRNA #1 and TrkC-siRNA #2 lentivirus were used in
two independent experiments (10 mice per experiments) and consistently yielded similar results. (B) Hematoxylin and eosin-stained sections of lungs from mice
injected with parental 4T1, 4T1 control-siRNA or 4T1 TrkC-siRNAs (magnification: 200). (C) Immunohistochemical analysis of TrkC protein levels in lungs
from mice injected with parental 4T1, 4T1 cells expressing control-siRNA or TrkC-siRNAs (magnification: 200). (D) Immunohistochemical analysis of
phospho-Akt levels in lungs from mice injected with parental 4T1, 4T1 cells expressing control-siRNA or TrkC-siRNAs (magnification: 200).
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Supplementary material
Supplementary Figures 1–3 and Table 1 can be found at http://carcin
.oxfordjournals.org/.
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